Researcher Neeraj Sood has explored innovative payment models as a strategy for government entities to be able to pay for lifesaving cures that could eradicate diseases like hepatitis C. Louisiana, with some input from Sood, has just implemented a modified version of a subscription model to pay for Hep C treatments.
Pharmaceutical Pricing and Medical Innovation
Other featured articles
The Use of Vendors in Medicare Part B Drug Payment
USC-Brookings Schaeffer Initiative experts provide an analysis of a voluntary vendor approach for Medicare to restrain drug spending for Part B drugs.
Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey
This paper examines racial/ethnic disparity in prescription drug cost-coping behaviors in a nationally representative sample of Medicare beneficiaries.
CMS’s International Pricing Model for Medicare Part B Drugs: Implementation Issues
To lower the Part B portion of drug spending, the Trump Administration has proposed a demonstration project tying Medicare reimbursement for outpatient, physician-administered drugs to international prices. Paul Ginsburg and Steven Lieberman explore the potential consequences of such a rule.
Louisiana’s Prescription Drug Experiment: A Model for the Nation?
On July 22, the USC-Brookings Schaeffer Initiative for Health Policy will hosted a conference on Louisiana's subscription model to expand access to Hepatitis C treatment for the state's incarcerated and Medicaid patients with the infection.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.